System Maintenance Notice

Please note that maintenance work is scheduled between 4 AM and 5 AM - CET. During this time, you may experience reduced performance. Thanks for your patience.

Christopher Halloran, MD, MBBS is an expert in Gastroenterology at Royal Liverpool University Hospital (United Kingdom). As of July 2026, ScienceLeadR ranks Christopher Halloran in the top 1% of experts worldwide for Pancreatic Diseases. Christopher Halloran has authored 217 publications, the most recent in 2026, and is an investigator in 5 clinical trials, 1 of them ongoing. SLR score: 571 (community average: 125). How the SLR is computed.

LeadR Profile

Christopher Halloran, MD, MBBS Royal Liverpool University Hospital United Kingdom
571 ScienceLeadR Reputation 571

Unlock

Register Login
Network Map

Gastroenterology

Subspecialties: Oncology - Surgery - Hepatology

Full career – Last 3 years

Main Topics

Publications and Clinical Studies

Publications – Clinical Studies

Profile data updated on

Organizations

Career arc: 2000 - 2026
Source: PubMed

Royal Liverpool University Hospital

Publications Synthesis

Sources: PubMed, OpenAlex

Number : 217

Citations

Citations: 8 125 1st author: 13 Last author: 21 Unique author: 23

Main journals

Pancreatology 74
Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature 23
Ann Surg 11
Cancer Res 6
Gut 6

Best Journals

J Clin Oncol 3
Lancet 3
Gut 1

Breakdown by type

Click a legend label to hide or show it in the chart.

Latest Publications

5 most recent indexed articles

Source: Pubmed

Title Journal Year Citations
The benefit of deep genomic testing for asymptomatic high-risk individuals undergoing surveillance for pancreatic adenocarcinoma: European registry for hereditary pancreatic diseases (EUROPAC-PLUS).
PMID 42361786 — registries, research design, genes, neoplasms, adenocarcinoma, mutation, pancreatic diseases		Neoplasia20260
DNA Origami and Their Application in Biosensors.
PMID 42187443 — dna, dna nanostructures		Biosensors (Basel)20260
Modelled impact of a multi-cancer early detection screening programme on cancer treatment in England.
PMID 42032201 — radiotherapy, early detection of cancer, neoplasms, multiple chronic conditions, therapeutics		Br J Cancer20260
Real-world outcomes following adjuvant chemotherapy for resected pancreatic cancer in a centralised oncology service.
PMID 41741817 — pancreatic neoplasms, neoplasms, drug therapy, chemotherapy, adjuvant, therapeutics, chemotherapy		Br J Cancer20260
Risk-stratified surveillance for individuals in the UK at high risk of developing pancreatic cancer: Outcomes from the European Registry of Hereditary Pancreatic Diseases (EUROPAC).
PMID 41740463 — registries, pancreatic neoplasms, neoplasms, wounds and injuries, pancreatic diseases		Eur J Cancer20260

Clinical Studies 5

Sources: ClinicalTrials, EU CTIS

Synthesis

Principal Investigator: 2

By phase:

Phase 3 3
N/A 1

By status:

Completed 3
Recruiting 1

By type:

Interventional 3
Observational 1

By Monocentric/Multicentric:

monocentric 3
multicentric2to4 0
multicentric5to9 0
multicentricup10 1

Main Topics

Ongoing Clinical Trials

Ongoing trial started since 2021, where this expert is an investigator

Source: ClinicalTrials

Study Phase Status Start
Volatile Organic Compound Assessment in Pancreatic Ductal Adenocarcinoma
NCT05727020 — anesthesia, pancreatic neoplasms, blood, neoplasms, adenocarcinoma, volatile organic compounds, signs and symptoms, organoids, endoscopy, specimen handling, therapeutics, tissues, breath tests, lipidomics		N/ARecruiting2022

LeadR Networks

Main global connection map

Sources: PubMed, OpenAlex, ClinicalTrials, EU CTIS